Skip to main content Skip to main navigation menu Skip to site footer

Terapi non bedah pada karsinoma sel basal

  • Adeline Santoso ,
  • I Gusti Ngurah Darmaputra ,
  • Dewi Gotama ,
  • Sissy Sissy ,


Basal cell carcinoma accounts for approximately 75% of non-melanoma skin cancer and 25% of all diagnosed skin cancer in the United States. Epidemiological data show the incidence is increasing significantly by 3% -10% per year worldwide. Changes in life expectancy patterns are associated with an increase in this skin cancer, and the incidence is predicted to increase until 2040. Many factors must be considered in the choice of therapy for a patient, including the patient's general condition, the presence or absence of serious medical problems, the use of antiplatelet or anticoagulant medication. Conservative treatment of asymptomatic and low-risk lesions is recommended, as overly aggressive therapy may have a greater effect than the lesions themselves. Topical therapy and non-surgical therapy are currently quite effective as therapeutic options for low-risk basal cell carcinoma and high-risk basal cell carcinoma. They can be an option in conditions that are contraindicated for surgery.



Kasus keganasan karsinoma sel basal (KSB) mencakup sekitar 75% dari kasus kanker kulit non melanoma dan mencakup 25% dari semua kasus kanker yang didiagnosa di Amerika Serikat.Data epidemiologi menunjukkan insiden meningkat signifikan sebanyak 3%-10% per tahun di seluruh dunia. Perubahan pola usia harapan hidup berhubungan dengan peningkatan kanker kulit ini, dan di prediksi insiden akan terus meningkat sampai tahun 2040. Terdapat banyak faktor yang harus dipikirkan dalam pemilihan terapi pada pasien, antara lain keadaan umum pasien, ada atau tidaknya masalah medis serius, penggunaan obat anti platelet atau anti koagulan. Perawatan konservatif pada lesi asimptomatik dan beresiko rendah dianjurkan, dikarenakan terapi yang terlalu agresif mungkin akan memberikan efek yang lebih besar dibandingkan dengan lesi itu sendiri. Saat ini terapi topikal dan terapi non-bedah dikatakan cukup efektif sebagai pilihan terapi untuk KSB resiko rendah dan KSB resiko tinggi serta dapat menjadi pilihan pada kondisi kontraindikasi terhadap tindakan pembedahan.


  1. Ariza S, Espinosa S, Naranjo M. Nonsurgical Therapies for Basal Cell Carcinoma: A Review. Actas Dermosifiliogr. 2017;108(9):809–17.
  2. Marzuka AG, Book SE. Basal cell carcinoma: Pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management. Yale J Biol Med. 2015;88(2):167–79.
  3. Akdeniz M, Hahnel E, Ulrich C, Blume-Peytavi U, Kottner J. Prevalence and associated factors of skin cancer in aged nursing home residents: A multicenter prevalence study. PLoS One. 2019;14(7):1–11.
  4. Bichakjian C, Armstrong A, Baum C, Bordeaux JS, Brown M, Busam KJ, et al. Guidelines of care for the management of basal cell carcinoma. J Am Acad Dermatol. 2018;78(3):540–59.
  5. Dika E, Scarfì F, Ferracin M, Broseghini E, Marcelli E, Bortolani B, et al. Basal cell carcinoma: A comprehensive review. Int J Mol Sci. 2020;21(15):1–11.
  6. Moore MG, Bennett RG. Basal Cell Carcinoma in Asians: A Retrospective Analysis of Ten Patients. J Skin Cancer. 2012;2012:1–5.
  7. Oh CM, Cho H, Won YJ, Kong HJ, Roh YH, Jeong KH, et al. Nationwide trends in the incidence of melanoma and non-melanoma skin cancers from 1999 to 2014 in south korea. Cancer Res Treat. 2018;50(3):729–37.
  8. Thomson J, Hogan S, Leonardi-Bee J, Williams HC, Bath-Hextall FJ. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev. 2020;2020(11).
  9. Kim DP, Kus KJB, Ruiz E. Basal Cell Carcinoma Review. Hematol Oncol Clin North Am. 2019;33(1):13–24.
  10. Fiona B-H, Perkins W. Basal cell carcinoma. In: Williams H, editor. Evidence Based Dermatology, 2nd ed. New Jersey: John Wiley & Sons; 2008. p. 256–71.
  11. Tang J, Epstein E, Oro A. Basal cell carcinoma and Basal Cell Nevus Syndrome. In: Kang S, Amagai M, Brucker A, Enk A, Margolis D, McMichael A, et al., editors. Fitzpatrick’s Dermatology in General Medicine, 9th ed. 2019. p. 1884–900.
  12. Lanoue J, Goldenberg G. Basal Cell Carcinoma. Clin Ophthalmic Oncol. 2016;9(5):26–36.
  13. Bostanci S, Kocyigit P, Vural S, Heper AO, Botsali A. Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma. Dermatol Surg. 2018;44(1):36–41.
  14. Singal A, Daulatabad D, Pandhi D, Arora V. Facial Basal Cell Carcinoma Treated with Topical 5% Imiquimod Cream with Dermoscopic Evaluation. J Cutan Aesthet Surg. 2016;9(2):122.
  15. Soong LC, Keeling CP. Cryosurgery + 5% 5-fluorouracil for treatment of superficial basal cell carcinoma and bowen’s disease. J Cutan Med Surg. 2018;22(4):400–4.
  16. Dos Santos AF, De Almeida DRQ, Terra LF, Baptista MS, Labriola L. Photodynamic therapy in cancer treatment - an update review. J Cancer Metastasis Treat. 2019;2019.
  17. Cohen DK, Lee PK. Photodynamic therapy for non-melanoma skin cancers. Cancers (Basel). 2016;8(10).
  18. Darmaputra IGN, Wardhana M, Adhilaksman IGN, Indira IGAAE, Suryawati N. Karsinoma sel basal tipe nodular yang diterapi dengan bedah eksisi elips dan anastesi tumesen. Intisari Sains Medis. 2019;10(1):192–6.
  19. Gonzalez LGV. Carcinoma basocelular. Tratamiento con interferon alfa 2b intralesional. Dermatologia Cosmet Medica y Quir. 2016;14(2):100–5.
  20. Fernández-Martori M, Bello-Rivero I, Duncan-Roberts Y. Treatment of basal cell carcinoma with interferons alpha-2b and gamma in primary care. MEDICC Rev. 2018;20(1):11–7.
  21. Fania L, Didona D, Di Pietro FR, Verkhovskaia S, Morese R, Paolino G, et al. Cutaneous squamous cell carcinoma: From pathophysiology to novel therapeutic approaches. Biomedicines. 2021;9(2):1–33.
  22. Fecher LA, Sharfman WH. Advanced basal cell carcinoma, the hedgehog pathway, and treatment options – Role of smoothened inhibitors. Biol Targets Ther. 2015;9:129–40.
  23. Silapunt S, Chen L, Migden MR. Hedgehog pathway inhibition in advanced basal cell carcinoma: Latest evidence and clinical usefulness. Ther Adv Med Oncol. 2016;8(5):375–82.
  24. Bello Rivero I. HeberFERON, a promising choice for the treatment of basal cell carcinoma. Integr Cancer Sci Ther. 2018;5(5):1–2.

How to Cite

Santoso, A., Darmaputra, I. G. N., Gotama, D., & Sissy, S. (2021). Terapi non bedah pada karsinoma sel basal. Intisari Sains Medis, 12(2), 723–727.




Search Panel